| 000 | 01494 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250515012213.0 | ||
| 264 | 0 | _c20060126 | |
| 008 | 200601s 0 0 eng d | ||
| 022 | _a1078-1552 | ||
| 024 | 7 |
_a10.1191/1078155205jp158cr _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTammaro, Kelly A | |
| 245 | 0 | 0 |
_aInterstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa). _h[electronic resource] |
| 260 |
_bJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners _cSep 2005 |
||
| 300 |
_a127-30 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aErlotinib Hydrochloride |
| 650 | 0 | 4 | _aGefitinib |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Diseases, Interstitial _xchemically induced |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aQuinazolines _xadverse effects |
| 650 | 0 | 4 | _aTomography, X-Ray Computed |
| 700 | 1 | _aBaldwin, Patricia D | |
| 700 | 1 | _aLundberg, Ante S | |
| 773 | 0 |
_tJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners _gvol. 11 _gno. 3 _gp. 127-30 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1191/1078155205jp158cr _zAvailable from publisher's website |
| 999 |
_c16008614 _d16008614 |
||